19 results about "Interferon gamma" patented technology

The invention discloses an engineered exosome for breaking through a pyroptosis immune starting and maintaining barrier as well as a preparation method and application of the engineered exosome. The exosome is constructed by loading an immune checkpoint inhibitor into a pre-stimulated exosome, and the exosome is derived from immune cells, high-expression interferon gamma and granzyme A. The expression of the tumor cell GSDMB is up-regulated by delivering the interferon gamma through the exosome, and the exogenous granzyme A cuts the GSDMB to trigger pyroptosis; meanwhile, an immune checkpoint inhibitor blocks a PD-1 / PD-L1 pathway in situ, T cell depletion is reversed, and release of endogenous granzyme A is promoted; the pyroptosis cells release antigens to activate the T cells, the activated T cells continuously secrete granzyme A / interferon gamma to form a cascade amplification effect, and the problem of double barriers existing in the pyroptosis immune cycle of granzyme A-GSDMB is solved. The engineered exosome can improve the infiltration degree of CD8 + T cells, and is suitable for treating tumors such as liver cancer and non-small cell lung cancer.

Compositions, kits, systems, and methods for reducing viability of cancer cells and treating cancer, as well as reducing a volume of a tumor and / or preventing an increase in volume of a tumor present in a body of a living subject, are disclosed. The systems and methods involve application of an alternating electric field in combination with administration of at least one composition comprising interferon gamma.

The invention relates to the technical field of cell biomedicine, in particular to umbilical cord mesenchymal stem cells with high PD-L1 expression, a culture method and application of the umbilical cord mesenchymal stem cells and a method for promoting PD-L1 expression through in-vitro energization. The umbilical cord mesenchymal stem cell in-vitro energizing inducer is based on a DMEM / F12 culture medium containing 3%-7% of human platelet lysis buffer, and further comprises the following components: a tumor necrosis factor alpha, interferon gamma, human serum albumin, transferrin, insulin, riboflavin, N-acetylcysteine and a vascular endothelial growth factor. The in-vitro energizing inducer reduces the content of a stimulating factor tumor necrosis factor alpha and interferon gamma, reduces immunogenicity abnormity caused by TNF-alpha, remarkably improves PDL1 expression and provides a basis for inflammation treatment. The influence of long-time stimulation on cell functions and activity is remarkably reduced through short-time factor-induced stimulation.

Methods of preparing mesenchymal stromal cells (MSCs) through co-stimulation with interferon gamma (IFNγ) and tumor necrosis factor alpha (TNFα), and methods for using the co-stimulated MSCs to treat conditions associated with exocrine glands. Co-treatment of MSCs with IFNγ and TNFα significantly enhances their trophic secretome, preserves their immunomodulatory capacity compared to untreated MSCs, and maximizes their therapeutic efficacy. The MSCs may be allogeneic to the recipient.

Provided is an anti-INF-γ antibody. Also provided are a composition comprising the antibody and a pharmaceutical application of the antibody in treating IFN-γ mediated syndrome.

The application discloses a DNA sulfur-modified bacillus subtilis and application thereof in alleviating alcoholic diseases, and relates to the field of biochemistry.The application provides a DNA sulfur-modified bacillus subtilis, which is named as Bacillus subtilis E10-1 and has a preservation number of CCTCC NO: M20253036.It is verified through animal experiments that the DNA sulfur-modified bacillus subtilis E10-1 is more resistant to alcohol than a strain in which sulfur modification is knocked out, can reduce the levels of indexes such as glutathione pyrotransaminase, glutathione transaminase and urea nitrogen in serum of a host after drinking alcohol, and the level of interferon gamma, can increase the levels of total protein, superoxide dismutase and glutathione peroxidase, can alleviate oxidative stress damage caused by alcohol, can reduce inflammatory reactions of various organ tissues, can maintain normal physiological functions of cells, can repair intestinal barriers, and can maintain intestinal flora homeostasis, so that alcoholic related diseases can be prevented and / or treated.

The application relates to the technical field of stem cells, in particular to a mesenchymal stem cell culture system without heterogeneity and application thereof. The mesenchymal stem cell culture system without heterogeneity comprises a basic culture medium and an additive component, wherein the basic culture medium is DMEM / F12, and the additive component comprises: recombinant human transferrin, recombinant human epidermal growth factor, recombinant human basic fibroblast growth factor, recombinant human insulin, recombinant human interferon gamma, hydrocortisone, vitamin A, vitamin D2, vitamin B, human blood albumin, CTS KnockOut SR XenoFree, glutamine and dextran. The mesenchymal stem cell culture system without heterogeneity provided by the application improves the proliferation efficiency of primary culture and in-vitro expansion culture of mesenchymal stem cells, is high in safety, good in stability and suitable for large-scale popularization and application.

The application discloses an egg white protein source peptide with the function of improving immunocompromise and application thereof, and belongs to the technical field of small molecule peptides. The egg white protein is subjected to enzymolysis by using a protease, and an albumin peptide is prepared by intercepting an enzymolysis product with a molecular weight less than 1000 Da, wherein the albumin peptide contains a tetrapeptide MSPF with the function of improving immunocompromise. Animal model function verification shows that the tetrapeptide MSPF and the albumin peptide containing the peptide segment can significantly improve immunocompromise, the number of macrophages is increased by 62.94%, the number of neutrophils is increased by 62.69%, and the content of interferon gamma is increased by 76.11%, thereby enhancing the immunity of the organism. The food-derived bioactive peptide has high biological safety. Therefore, the tetrapeptide MSPF or the albumin peptide containing the peptide segment can be applied to the preparation of medicines for improving immunocompromise or health care food for enhancing immunity, and has good market prospect and application potential.

The invention discloses an egg white protein source peptide with an effect of improving immunocompromise and application of the egg white protein source peptide, and belongs to the technical field of small molecule peptides. Protease is used for carrying out enzymolysis on egg white protein, an enzymolysis product with the molecular weight smaller than 1000 Da is cut out to prepare albumin peptide, and the albumin peptide contains tetrapeptide MSPF with the effect of improving the immunocompromise. Animal model function verification shows that the tetrapeptide MSPF and the albumin peptide containing the peptide fragment can significantly improve low immune function, the number of macrophages is increased by 62.94%, the number of neutrophils is increased by 62.69%, and the content of interferon gamma is increased by 76.11%, so that the immunity of the organism is enhanced. The food-borne bioactive peptide is high in biological safety. Therefore, the tetrapeptide MSPF or the albumin peptide containing the peptide fragment can be applied to the preparation of medicines for improving immunocompromise or health-care foods for enhancing immunity, and has good market prospects and application potential.

The present invention relates to the diagnosis and treatment of conditions in patients with elevated levels of CXCL9 and other biomarkers. Methods and compositions for the treatment of hemophagocytic lymphocytosis (HLH) are provided. The present disclosure also generally relates to methods and compositions for diagnosing and treating conditions associated with elevated levels of CXCL9, elevated levels of total IFN gamma, and other biomarkers. The present disclosure also relates to methods of treating, delaying the progression or otherwise ameliorating the symptom of a condition in a patient with elevated levels of CXCL9, elevated levels of total IFN gamma and other biomarkers using agents that intervene in or otherwise antagonize interferon gamma (IFN gamma) signaling, including neutralizing anti-IFN gamma antibodies.

Aspects of the disclosure relate to compositions and methods for modulating the immune response of a subject. The disclosure is based, in part, on compositions comprising one or more compounds that promotes interferon, e.g., interferon gamma (IFNγ), response in the gut microbiome of a subject and / or enhances the anti-tumor effects of certain immune checkpoint inhibitor (ICI) therapies. In some embodiments, the compositions are useful for treating a subject having cancer.

The invention provides an SNP (Single Nucleotide Polymorphism) molecular marker related to pig immune traits, which is located at the 54707402 site of the sixth chromosome of a pig reference genome Susscrofa.Sscrofa11.1 version, and has T / C polymorphism; wherein the C allelic group is used as a dominant allele for improving the serum interferon gamma concentration, and the serum IFN-gamma concentration of a pig individual with the genotype of CC is obviously higher than that of an individual with the genotype of TT or TC; the molecular marker has the beneficial effects that the technical scheme provided by the invention provides a new molecular marker resource with clear genetic effect, reliable typing method and good cross-population stability for pig breeding for disease resistance.

The invention provides a factor combination for improving the anti-pulmonary fibrosis capability of mesenchymal stem cells and reducing the risk of pulmonary thrombosis and application of the factor combination, and relates to the technical field of biology. The factor composition comprises (I) interferon gamma, wherein the acting concentration of the interferon gamma is 0.5-5ng / mL; and (II) an interleukin 4 and / or a tumor necrosis factor alpha, the action concentration of the interleukin 4 being 1-20 ng / mL, and the action concentration of the tumor necrosis factor alpha being 1-25 ng / mL. The mesenchymal stem cells treated by the factor combination not only can improve the anti-pulmonary fibrosis ability of the mesenchymal stem cells, but also can regulate the expression of CD142 in the mesenchymal stem cells and reduce the risk of pulmonary thrombosis of the mesenchymal stem cells, does not promote the occurrence of inflammations, is beneficial to improving the treatment effect and prognosis of patients with lung diseases, and has a wide application prospect. And a new thought is provided for clinical application of MSC in lung diseases.

The current disclosure provides for a method for stratifying patients based on their predicted efficacy to an immunotherapy. Accordingly, provided herein is a method for treating a subject for brain cancer, the method comprising administering to the subject an immunotherapy, wherein the subject has been determined be negative or low for an interferon gamma activation response in a biological sample from the patient. Also described is a method for predicting patient outcomes and / or for predicting the effectiveness of an immunotherapy for treating brain cancer in a subject in need thereof, the method comprising determining an interferon gamma activation response from a biological sample from the subject. Also provided is a method for evaluating a subject having brain cancer, the method comprising determining an interferon gamma activation response in a biological sample from the subject.

Compositions, kits, systems, and methods for reducing viability of cancer cells and treating cancer, as well as reducing a volume of a tumor and / or preventing an increase in volume of a tumor present in a body of a living subject, are disclosed. The systems and methods involve application of an alternating electric field in combination with administration of at least one composition comprising interferon gamma.

The invention belongs to the technical field of gene engineering, and particularly discloses construction and application of an oncolytic virus for providing replication selectivity through a promoter and mir-TS. The oncolytic virus comprises an MAGEA6 promoter, a miR-TS coding sequence and a human interferon gamma-hIFNG coding gene. The invention discloses construction and application of an oncolytic virus for providing replication selectivity through a promoter and mir-TS. The oncolytic virus can effectively improve the oncolytic effect and reduce the system toxicity. According to the invention, the MAGEA6 promoter is combined with miR-TS for adenovirus modification for the first time, and a new strategy is provided for targeted therapy of MAGEA6 high-expression tumors.

The present invention provides a novel construct comprising gold nanoparticles bound to two types of cytokines, where the two types of cytokines comprise Tumor Necrosis Factor alpha (TNF) and a cytokine selected from the group consisting of Interferon Gamma (IFN) and Interleukin-12. The invention also provides a method for cancer treatment of a subject in need thereof.

The invention provides a marker composition, a kit and a prediction and evaluation method for evaluating the risk of immune reconstitution insufficiency of an HIV (Human Immunodeficiency Virus) infected person, and the marker composition, the kit and the prediction and evaluation method are used for predicting and evaluating the risk of immune reconstitution insufficiency of the HIV infected person by adopting the combination of three markers of an interferon gamma-induced mononuclear cell chemokine (MIG), a nerve growth factor (NGF) and granzyme B (GZMB). Effective evaluation and auxiliary diagnosis of the risk of incomplete immune reconstitution (INR) of an HIV infected person under long-term anti-retrovirus treatment are realized, the prediction sensitivity, specificity and stability are improved, and a basis is provided for clinical early intervention and individualized management.

The present disclosure relates to bispecific antibodies directed against interferon gamma (IFN gamma) and tumor-associated antigens to deliver IFN gamma to a tumor, and to medical uses of such antibodies.